Notice of Annual General Meeting
Released
Released
Announcement PDF
ALTERITY THERAPEUTICS LIMITED
ACN 080 699 065
Notice of Annual General Meeting
and Explanatory Memorandum
Time and Date of Meeting:
9.00am (AEDT) on Friday, 22 November 2024
Registration from 8.30am
Location:
Deloitte Australia Offices
Level 30, 477 Collins Street,
Melbourne VIC 3000
Voting ahead of attending the Meeting
Shareholders are strongly encouraged to vote by lodging a directed proxy appointing the Chair before 9.00am (AEDT)
on Wednesday, 20 November 2024. Instructions for lodging proxies are included on your personalised proxy form, or
in the link that you received if you provided an email address. Alternatively, you are able to vote ahead of the Meeting
via https://investor.automic.com.au/#/loginsah
This is an important document. It should be read in its entirety.
If you are in doubt as to the course you should follow, consult your financial or other professional adviser.
NOTICE OF 2024 ANNUAL GENERAL MEETING
ALTERITY THERAPEUTICS LIMITED
ACN 080 699 065
Notice is given that the 2024 Annual General Meeting of Alterity Therapeutics Limited (“the Company” or
"Alterity") will be held at Deloitte Australia Offices, L30, 477 Collins Street, Melbourne VIC at 9.00am (AEDT) on
Friday, 22 November 2024, for the purposes of considering and, if thought fit, passing each of the resolutions
referred to in this Notice of Annual General Meeting.
Further details in respect of each of the resolutions proposed in this Notice of Annual General Meeting are set
out in the Explanatory Memorandum accompanying this Notice of Annual General Meeting. The details of the
resolutions contained in the Explanatory Memorandum should be read together with, and form part of, this
Notice of Annual General Meeting.
Please read this Notice of Annual General Meeting carefully and consider directing your proxy on how to vote
on each resolution by marking the appropriate box on the proxy form included with this Notice of Annual General
Meeting. Shareholders who intend to appoint the Chair as proxy (including appointment by default) should have
regard to Proxy and Voting Instructions on page 7 of this Notice of Annual General Meeting.
ORDINARY BUSINESS
2024 Annual Reports
To receive and consider the 2024 Annual Financial Statements of the Company in respect of the year ended 30
June 2024 comprising the Annual Financial Report, the Directors’ Report and the Auditor’s Report. At the
meeting, a representative of the Company's auditors, PricewaterhouseCoopers, will be invited to attend to
answer questions about the audit of the Company’s 2024 Annual Financial Statements.
Resolution 1 – Non-binding resolution to adopt Remuneration Report
To consider and, if thought fit, to pass the following resolution as an advisory and non-binding ordinary
resolution:
"THAT for the purposes of section 250R(2) of the Corporations Act, the Remuneration Report for the financial
year ended 30 June 2024 as disclosed in the Directors' Report is adopted."
Voting Prohibition – Corporations Act
A vote on Resolution 1 must not be cast (in any capacity) by or on behalf of either of the following persons:
•
a member of the key management personnel, details of whose remuneration are included in the Remuneration
Report; or
•
a closely related party of such a member (referred to herein as Restricted Voters).
However, a person (voter) may cast a vote on Resolution 1 as a proxy if the vote is not cast on behalf of a Restricted Voter
and the voter is appointed as a proxy in writing that specifies the way the proxy is to vote on Resolution 1. The Chair may
also exercise undirected proxies if the vote is cast on behalf of a person entitled to vote on Resolution 1 and the proxy
appointment expressly authorises the Chair to exercise the proxy even if Resolution 1 is connected directly or indirectly with
the remuneration of members of the key management personnel of the Company.
Voting Note:
Directors of the Company who are key management personnel whose remuneration details are included in the 2024
Remuneration Report, any other key management personnel whose remuneration details are included in the 2024
Remuneration Report, or any of their closely related parties, will not be able to vote on Resolution 1 or to vote undirected
Page 2 of 22
NOTICE OF 2024 ANNUAL GENERAL MEETING
proxies held by them on Resolution 1.
Resolution 2 – Re-Election of Director – Mr Geoffrey Kempler
To consider and, if thought fit, pass as an ordinary resolution, the following:
"THAT: Mr Geoffrey Kempler, a Director of the Company, who retires by rotation in accordance with the
Company's Constitution and, being eligible, offers himself for re-election, be re-elected as a Director of the
Company."
Resolution 3 – Ratification of prior issue of shares (Placement July 2024)
To consider and, if thought fit, pass as an ordinary resolution, the following:
"THAT for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders ratify the prior issue
of 75,220,800 fully paid ordinary shares at A$0.0054 (0.54 Australian cents) per share to unrelated
professional, sophisticated and other investors exempt from the disclosure requirements of Ch 6D of the
Corporations Act as described in the Explanatory Memorandum which accompanied and formed part of the
Notice of Annual General Meeting."
Voting Exclusion Statement – ASX Listing Rules
The Company will disregard any votes cast in favour of Resolution 3 by or on behalf of a person who participated in the issue
or is a counterparty to the agreement being approved or any associate of that person.
However, this does not apply to a vote cast in favour of Resolution 3 by:
•
a person as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with the directions
given to the proxy or attorney to vote on the resolution in that way; or
•
the chair of the Meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with
a direction given to the chair to vote on the resolution as the chair decides; or
•
a holder acting solely as nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the
following conditions are met:
o
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting,
and is not an associate of a person excluded from voting, on the resolution; and
o
the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote
in that way.
Resolution 4 – Approval for issue of options – Mr Geoffrey Kempler
To consider and, if thought fit, pass as an ordinary resolution, the following:
"THAT for the purposes of Listing Rule 10.11, Chapter 2E and section 195(4) of the Corporations Act and for
all other purposes, shareholders approve the issue of 60,000,000 unlisted options (each with an exercise
price of A$0.01 (1 Australian cent), expiring three years from issue and, upon exercise, entitling the holder to
one fully paid ordinary share in the Company) to Mr Geoffrey Kempler (and/or his nominee(s)) as described
in the Explanatory Memorandum which accompanied and formed part of the Notice of Annual General
Meeting."
A voting exclusion statement, voting prohibition and proxy voting prohibition applies to this Resolution. Please
see below.
Page 3 of 22
NOTICE OF 2024 ANNUAL GENERAL MEETING
Resolution 5 - Approval for issue of options – Mr Lawrence Gozlan
To consider and, if thought fit, pass as an ordinary resolution, the following:
"THAT for the purposes of Listing Rule 10.11, Chapter 2E and section 195(4) of the Corporations Act and for
all other purposes, shareholders approve the issue of 50,000,000 unlisted options (each with an exercise
price of A$0.01 (1 Australian cent), expiring three years from issue and, upon exercise, entitling the holder to
one fully paid ordinary share in the Company) to Mr Lawrence Gozlan (and/or his nominee(s)) as described
in the Explanatory Memorandum which accompanied and formed part of the Notice of Annual General
Meeting."
A voting exclusion statement, voting prohibition and proxy voting prohibition applies to this Resolution. Please
see below.
Resolution 6 – Approval for issue of options – Mr Peter Marks
To consider and, if thought fit, pass as an ordinary resolution, the following:
"THAT for the purposes of Listing Rule 10.11, Chapter 2E and section 195(4) of the Corporations Act and for
all other purposes, shareholders approve the issue of 30,000,000 unlisted options (each with an exercise
price of A$0.01 (1 Australian cent), expiring three years from issue and, upon exercise, entitling the holder to
one fully paid ordinary share in the Company) to Mr Peter Marks (and/or his nominee(s)) as described in the
Explanatory Memorandum which accompanied and formed part of the Notice of Annual General Meeting."
A voting exclusion statement, voting prohibition and proxy voting prohibition applies to this Resolution. Please
see below.
Resolution 7 – Approval for issue of options – Mr Brian Meltzer
To consider and, if thought fit, pass as an ordinary resolution, the following:
"THAT for the purposes of Listing Rule 10.11, Chapter 2E and section 195(4) of the Corporations Act and for
all other purposes, shareholders approve the issue of 30,000,000 unlisted options (each with an exercise
price of A$0.01 (1 Australian cent), expiring three years from issue and, upon exercise, entitling the holder to
one fully paid ordinary share in the Company) to Mr Brian Meltzer (and/or his nominee(s)) as described in
the Explanatory Memorandum which accompanied and formed part of the Notice of Annual General
Meeting."
A voting exclusion statement, voting prohibition and proxy voting prohibition applies to this Resolution. Please
see below.
Voting Exclusion Statement – ASX Listing Rules - Resolutions 4 to 7
The Company will disregard any votes cast in favour of Resolutions 4 to 7 respectively by or on behalf of the person who is
to receive the securities in question and any other person who will obtain a material benefit as a result of the issue of the
securities (except a benefit solely by reason of being a holder of ordinary securities in the entity) and any of their associates.
However, this does not apply to a vote cast in favour of Resolutions 4 to 7 respectively by:
•
a person as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with the directions
given to the proxy or attorney to vote on the resolution in that way; or
•
the chair of the Meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with
a direction given to the chair to vote on the resolution as the chair decides; or
•
a holder acting solely as nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the
following conditions are met:
Page 4 of 22
NOTICE OF 2024 ANNUAL GENERAL MEETING
o
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting,
and is not an associate of a person excluded from voting, on the resolution; and
o
the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote
in that way.
Voting Prohibition – Chapter 2E of the Corporations Act – Resolutions 4 to 7
In accordance with section 224 of the Corporations Act, a vote on Resolutions 4 to 7 (which seek shareholder approval for
the purposes of Chapter 2E of the Corporations Act) must not be cast (in any capacity) by or on behalf of:
•
a related party of the Company to whom Resolutions 4 to 7 respectively would permit a financial benefit to be given;
or
•
an associate of such a related party.
However, the above does not prevent the casting of a vote if:
•
it is cast by a person as proxy appointed by writing that specifies how the proxy is to vote on the proposed resolution;
and
•
it is not cast on behalf of a related party or associate of a kind referred to above.
Proxy Voting Prohibition – Restricted Voters – Corporations Act – Resolutions 4 to 7
Other than as set out below, a vote on Resolutions 4 to 7 respectively must not be cast as proxy by a Restricted Voter (defined
above).
A Restricted Voter may cast a vote on Resolutions 4 to 7 respectively as a proxy if either:
•
the Restricted Voter is appointed as a proxy by writing that specifies the way the proxy is to vote on this resolution; or
•
the Restricted Voter is the chair and the written appointment of the chair as proxy:
o
does not specify the way the proxy is to vote on this resolution; and
o
expressly authorises the chair to exercise the proxy even though this resolution is connected directly or indirectly
with the remuneration of a member of the Key Management Personnel.
SPECIAL BUSINESS
Resolution 8 – Approval of 10% Placement Issue
To consider and, if thought fit, pass the following as a special resolution:
"THAT, pursuant to and in accordance with ASX Listing Rule 7.1A and for all other purposes, the Company
may elect to issue equity securities up to 10% of the issued capital of the Company (at the time of issue)
calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 and on the terms and
conditions described in the Explanatory Memorandum which accompanied and formed part of this Notice of
Annual General Meeting."
Voting Exclusion Statement – ASX Listing Rules
The Company will disregard any votes cast in favour of Resolution 8 by or on behalf of any person who is expected to
participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of
being a holder of ordinary securities in the entity) or any associate of that person.
However, this does not apply to a vote cast in favour of Resolution 8 by:
Page 5 of 22
NOTICE OF 2024 ANNUAL GENERAL MEETING
•
a person as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with the directions
given to the proxy or attorney to vote on the resolution in that way; or
•
the chair of the Meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with
a direction given to the chair to vote on the resolution as the chair decides; or
•
a holder acting solely as nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the
following conditions are met:
o
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting,
and is not an associate of a person excluded from voting, on the resolution; and
o
the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote
in that way.
OTHER BUSINESS
To consider any other business that may be brought before the Meeting in accordance with the Constitution of
the Company and the Corporations Act.
Further details in respect of these Resolutions are set out in the Explanatory Memorandum accompanying this
Notice of Annual General Meeting.
By the order of the Board:
Geoffrey Kempler
Chairman
Alterity Therapeutics Limited
Dated: 23 October 2024
The accompanying Explanatory Memorandum, Proxy Form
and Voting Instructions form part of this Notice of Annual General Meeting.
Page 6 of 22
NOTICE OF 2024 ANNUAL GENERAL MEETING
PROXY AND VOTING INSTRUCTIONS
Proxy Instructions
A Shareholder who is entitled to attend and vote at this
meeting may appoint:
(a)
one proxy if the Shareholder is only entitled to one
vote; and
(b)
one or two proxies if the Shareholder is entitled to
more than one vote.
Where more than one proxy is appointed each proxy may be
appointed to represent a specific proportion of the
Shareholder's voting rights. If the appointment does not specify
the proportion or number of votes each proxy may exercise,
each proxy may exercise half of the votes, in which case any
fraction of votes will be disregarded.
The proxy may, but need not, be a member of the Company.
Where a Shareholder appoints two proxies, on a poll each
proxy may only exercise votes in respect of those shares or
voting rights the proxy represents.
Proxies may be lodged using any of the following methods:
online
by
visiting
https://investor.automic.com.au/#/loginsah o
by returning a completed Proxy Form by post to:
Automic, GPO Box 5193 Sydney NSW 2001
by faxing a completed Proxy Form to +61 2 8583 3040 by
email to meetings@automicgroup.com.au
not less than 48 hours before the time for holding the Meeting,
or adjourned meeting as the case may be, at which the
individual named in the proxy form proposes to vote.
The proxy form must be signed by the Shareholder (or in the
case of a joint holding, by each joint holder) or his/her attorney
duly authorised in writing or, if the member is a corporation, in
a manner permitted by the Corporations Act. A proxy given by
a foreign corporation must be executed in accordance with the
laws of that corporation’s place of incorporation.
If you sign the proxy form and do not appoint a proxy, you will
have appointed the Chair of the Meeting as your proxy.
The appointment of one or more duly appointed proxies will
not preclude a Shareholder from attending this meeting and
voting personally. If the Shareholder votes on a resolution, the
proxy must not vote as the Shareholder’s proxy on that
resolution. A proxy form is attached to this Notice.
How the Chair will vote undirected proxies
Subject to the restrictions set out in the Notice, the Chair of
the meeting will vote undirected proxies on, and in favour of,
all of the proposed resolutions.
Corporate Representatives
Any corporation which is a Shareholder of the Company may
appoint a proxy, as set out above, or authorise (by certificate
under common seal or other form of execution authorised by
the laws of that corporation’s place of incorporation, or in any
other manner satisfactory to the Chairperson of the meeting)
a natural person to act as its representative at any general
meeting.
Corporate representatives are requested to bring appropriate
evidence of appointment as a representative in accordance
with the constitution of the Company. Attorneys are
requested to bring the original or a certified copy of the power
of attorney pursuant to which they were appointed. Proof of
identity will also be required for corporate representatives
and attorneys.
Voting Entitlement
For the purposes of section 1074E(2)(g)(i) of the Corporations
Act and Regulation 7.11.37 of the Corporations Regulations,
the Board has determined that Shareholders entered on the
Company’s Register of Members as at20 November 2024 at
7:00 pm (AEDT) are entitled to attend and vote at the
meeting. Transactions registered after that time will be
disregarded in determining the Shareholders entitled to
attend and vote at the meeting.
On a poll, Shareholders have one vote for every fully paid
ordinary share held. Holders of options are not entitled to
vote.
In the case of joint holders of shares, if more than one holder
votes at any meeting, only the vote of the first named of the
joint holders in the share register of the Company will be
counted.
Special Resolution
Resolution 8 is proposed as special resolution. For a special
resolution to be passed, at least 75% of the votes validly cast
on the resolution by shareholders (by number of shares) must
be in favour of the resolution.
Page 7 of 22
EXPLANATORY MEMORANDUM
ALTERITY THERAPEUTICS LIMITED
ACN 080 699 065
("the Company")
2024 ANNUAL GENERAL MEETING
PURPOSE OF INFORMATION
This Explanatory Memorandum ("Memorandum") accompanies and forms part of the Company’s Notice of the
2024 Annual General Meeting ("Meeting") to be held at Deloitte Australia Offices, L30, 477 Collins Street,
Melbourne VIC, at 9.00am (AEDT) on Friday, 22 November 2024. The Notice of the 2024 Annual General Meeting
("the Notice") incorporates, and should be read together with, this Memorandum.
ORDINARY BUSINESS
2024 Annual Reports
The 2024 Annual Financial Statements, comprising the Financial Report, Directors' Report and Auditor's Report
for the year ended 30 June 2024 will be laid before the meeting. Shareholders will have the opportunity to ask
questions about or make comments on the 2024 Annual Financial Statements and the management of the
Company. A representative of the auditor will be invited to attend to answer questions about the audit of the
Company’s 2024 Annual Financial Statements.
The Company’s 2024 Annual Financial Statements are set out in the Company’s 2024 Annual Report which can
be obtained from the Company’s website, www.alteritytherapeutics.com or upon request to the Company
Secretary by email to info@alteritytherapeutics.com.
There is no requirement for these reports to be formally approved by Shareholders. No resolution is required to
be moved in respect of this item.
Resolution 1: Non-binding Resolution - Remuneration Report
Background
Pursuant to the Corporations Act 2001 (Cth) (“Corporations Act”) at the Annual General Meeting (“AGM”) of a
listed company, that company must propose a resolution that the Remuneration Report be adopted.
The purpose of this resolution is to present to the Shareholders the Company’s Remuneration Report so that
Shareholders may ask questions about or make comments on the management of the Company in accordance
with the requirements of the Corporations Act and vote on whether to adopt the Remuneration Report for the
year ended 30 June 2024.
This resolution is advisory only and does not bind the Company, however the Board will consider the outcome
of the vote made by Shareholders on the remuneration report at the meeting when reviewing the Company’s
remuneration policies. Under the Corporations Act, if 25% or more of votes that are cast are voted against the
adoption of the Remuneration Report at two consecutive AGMs (treating this AGM as the first such meeting),
shareholders will be required to vote at the second of those AGM's on a resolution (a "spill resolution") that
another meeting be held within 90 days at which all of the Company's Directors (other than the Managing
Director and CEO) must be put up for re-election. The vote on the Remuneration Report contained in the
Company’s 2023 Annual Financial Statement was passed with the support of more than 75% of votes thus a spill
resolution will not be required in the event 25% or more of the votes that are cast at the 2024 AGM are against
the adoption of the 2024 Remuneration Report. However, in the event that 25% or more of votes that are cast
Page 8 of 22
EXPLANATORY MEMORANDUM
are against the adoption of the 2024 Remuneration Report, shareholders should be aware if there is a ‘no’ vote
of 25% or more for the same resolution at the 2025 AGM it may result in the re-election of the Board.
The Remuneration Report is contained within the 2024 Annual Report. You may access the Annual Report by
visiting the Company’s website www.alteritytherapeutics.com.
Resolution 2: Re-Election of Director – Mr. Geoffrey Kempler
At each AGM of the Company, one third of the Directors of the Company must retire from office by rotation, in
accordance with the Company’s Constitution. The Managing Director is not subject to rotation. No Director
(except the Managing Director) shall retain office for a period in excess of three years without submitting himself
or herself for re-election. A Director who retires from office by rotation and is eligible for re-election may offer
him or herself for re-election.
Mr Geoffrey Kempler retires by rotation and, being eligible, offer himself for re-election. A biography for Mr
Geoffrey Kempler is set out below:
Mr. Geoffrey Kempler has served as Chairman of the Board of Directors since November 1997; between November
1997 and August 2004 he served as the Chief Executive Officer and again assumed the position of Chief Executive
Officer from June 2005 until January 2021. Mr. Kempler is one of the founders of our company.
Mr. Kempler qualified as psychologist with extensive experience in investment and business development. He
served as a Chairman and Non-Executive Director of Opthea Limited (NASDAQ:OPT), from November 2015 until
October 2020, is immediate past Chairman of Ausbiotech, Australia’s biotechnology organization, and is a member
of the Industry Advisory Board at the Turner Institute of Brain and Mental Health at Monash University, and Chair
of Hexima Ltd. Mr. Kempler holds a B.Sc degree in science from Monash University, Grad. Dip. App. Soc. Psych.
degree from Swinburne University.
The board of Directors (with Mr Geoffrey Kempler abstaining from making a recommendation) recommend that
shareholders vote in favour of Resolution 2.
Resolution 3 – Ratification of prior issue of shares (Placement July 2024)
Resolution 3 seeks shareholder ratification for the purposes of ASX Listing Rule 7.4 for the prior issue of the
75,220,800 fully paid ordinary shares at an issue price of A$0.0054 (0.54 Australian cents) per share to unrelated
sophisticated, professional and other investors exempt from the disclosure requirements of Chapter 6D of the
Corporations Act who were identified by the Company, raising approximately A$406,192.32 before costs.
The shares were issued under the placement capacity available to the Company under ASX Listing Rule 7.1A on
18 July 2024 and an Appendix 2A for the issue of the shares was released to ASX on 19 July 2024. The Company
obtained shareholder approval to make issues under the placement capacity available under ASX Listing Rule
7.1A at its 2023 AGM held on 29 November 2023.
ASX Listing Rule 7.4 provides that where a company’s shareholders ratify the prior issue of securities made
pursuant to ASX Listing Rule 7.1 and/or 7.1A (provided that the previous issue of securities did not breach ASX
Listing Rule 7.1 and/or 7.1A) those securities will be deemed to have been issued with shareholder approval for
the purposes of ASX Listing Rule 7.1 and/or 7.1A. The Company seeks approval under Listing Rule 7.4 to refresh
its capacity to make further issues without shareholder approval under Listing Rule 7.1 and/or Listing Rule 7.1A.
If shareholders pass Resolution 3 then the fully paid ordinary shares the subject of Resolution 3 will be treated
as not having used the placement capacity of the Company available under the ASX Listing Rules. The fully paid
ordinary shares will also increase the placement capacity available to the Company under the ASX Listing Rules.
Page 9 of 22
EXPLANATORY MEMORANDUM
If shareholders do not pass Resolution 3 then the fully paid ordinary shares the subject of Resolution 3 will
continue to use the placement capacity available to the Company under the ASX Listing Rules.
The following information is provided in accordance with the requirements of ASX Listing Rule 7.5:
• The securities were issued to unrelated sophisticated, professional and other investors exempt from the
disclosure requirements of Chapter 6D of the Corporations Act who were identified by the Company.
• The total number of securities issued was 75,220,800 fully paid ordinary shares.
• The shares issued have the same terms and rights as, and rank equally with, the Company’s other fully paid
ordinary shares on issue.
• The shares were issued on 18 July 2024 and an Appendix 2A was released to ASX on 19 July 2024.
• The shares were issued at A$0.0054 (0.54 Australian cents) per share.
• A$406,192.32 was raised from the issue of the shares the subject of Resolution 3. Funds raised have been,
or will be, used for further research and development activities and to provide ongoing working capital.
• A voting exclusion statement for Resolution 3 is contained in the Notice accompanying this Memorandum.
The Directors unanimously recommend shareholders vote in favour of Resolution 3.
Resolutions 4 to 7 – Approval for issue of options - related parties
Resolutions 4 to 7 seek shareholder approval for the purposes of ASX Listing Rule 10.11, Chapter 2E and section
195(4) of the Corporations Act and for all other purposes to issue an aggregate of 170,000,000 unlisted options
(each with an exercise price of A$0.01 (1 Australian cent), expiring three (3) years from issue and which, upon
exercise, entitle the holder to one fully paid ordinary share in the capital of the Company) to the Directors of the
Company (and/or their nominee(s)). The full terms of the unlisted options A.
The proposed recipient, number of unlisted options they are proposed to receive are set out in the table below:
Res #
Proposed recipient*
Number of options
4
Geoffrey Kempler
60,000,000
5
Lawrence Gozlan
50,000,000
6
Peter Marks
30,000,000
7
Brian Meltzer
30,000,000
TOTAL
170,000,000
*unlisted options may be issued to nominee(s) as advised to the Company.
ASX Listing Rules
ASX Listing Rule 10.11 requires a company to obtain shareholder approval by ordinary resolution prior to the
issue of securities to a related party of the company or any of their associates or any person whose relationship
with either of those persons is such that in ASX’s opinion the acquisition should be approved by shareholders.
Page 10 of 22
EXPLANATORY MEMORANDUM
Shareholder approval is being sought under Listing Rule 10.11 for Resolutions 4 to 7 and as such approval is not
required under ASX Listing Rule 7.1.
If shareholders:
•
Pass all of Resolutions 4 to 7, the Company will be able to issue all of the unlisted options the subject of
those Resolutions. In addition, shares issued on exercise of these unlisted options (if any) will increase the
placement capacity available to the Company.
•
Pass some, but not all, of Resolutions 4 to 7, the Company will be able to issue the unlisted options the
subject of the Resolution(s) passed by shareholders, but will not be able to issue the unlisted options the
subject of the Resolution(s) not passed by shareholders. In addition, shares issued on exercise of unlisted
options issued in respect of
Share your feedback
Discover